88 results about "Myeloma cell" patented technology

The invention provides a monoclonal antibody capable of recognizing a recombinant EGF-CRM197 vaccine and a preparation method thereof, on the basis of researching, developing and preparing the recombinant EGF-CRM197 vaccine, after the recombinant EGF-CRM197 vaccine is further immunized and inoculated to a mouse, mouse spleen cells and mouse myeloma cells are fused, and the monoclonal antibody capable of recognizing the recombinant EGF-CRM197 vaccine is obtained. And screening a hybridoma cell strain which generates a specific monoclonal antibody for recognizing the recombinant EGF-CRM197 vaccine, and sequencing to obtain an antibody sequence. After the hybridoma cells are cultured in a mouse body, the monoclonal antibody for recognizing the recombinant EGF-CRM197 vaccine can be prepared in vitro through methods of chromatographic purification and the like. The method can be used for detecting the release titer of the recombinant EGF-CRM197 vaccine and evaluating the immune efficacy after the recombinant EGF-CRM197 vaccine is immunized.

The present invention discloses a nano antibody against BCMA and its preparation method and application, and relates to the field of biomedical technology. The present invention uses CRISPR / Cas9 technology to knock out B2M and TRAC genes in T cells to prepare universal CAR-T cells; the nano antibody targeting BCMA and the natural ligand SIRPα extracellular N-terminal V region of CD47, the transmembrane region of CD28, the intracellular signal region of 4-1BB and the intracellular signal region of CD3ζ are connected in series to form a dual-targeted chimeric antigen receptor for the treatment of multiple myeloma, so as to solve the high recurrence problem faced by CAR-T cell therapy in the treatment of multiple myeloma. The universal CAR-T cells prepared by the present invention have strong killing activity against multiple myeloma cells, effectively improve the treatment effect, and provide a key material for the subsequent development of adoptive immunotherapy with high efficiency and lasting anti-tumor activity.

The invention discloses a monoclonal antibody targeting all CD45 subtypes and application of the monoclonal antibody, and belongs to the field of monoclonal antibody preparation. The hybridoma cell strain capable of stably secreting all anti-human CD45 subtype antibodies is successfully obtained by stably expressing short and long molecular subtypes of human CD45 extracellular regions in L929 mouse fibroblasts, immunizing BALB / c mice with L929 cells expressing the two molecular subtypes of human CD45, and fusing splenocytes with SP20 myeloma cells after the serum titer reaches the standard. And the monoclonal antibody targeting all subtypes of CD45 is obtained. The monoclonal antibody provided by the invention shows a high-affinity binding characteristic with all human CD45 molecular subtypes, has important application value in the aspect of human CD45 molecular detection, and can be used as a therapeutic antibody in the fields of tumor immunotherapy, autoimmune disease treatment, transplant rejection resistance and the like.

The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.

The invention belongs to the technical field of biology, provides an anti-IL-8 monoclonal antibody, a variable region sequence of the anti-IL-8 monoclonal antibody and application of the anti-IL-8 monoclonal antibody, and discloses a monoclonal antibody with neutralizing interleukin-8 (IL-8) biological activity and the variable region sequence of the monoclonal antibody. The preparation method comprises the following steps: by taking IL-8 as an immune source and a mouse as an immune object, carrying out immune injection on the mouse, taking the spleen of the immune mouse to prepare a suspension, and carrying out cell fusion on the suspension and myeloma cells to obtain a hybridoma cell strain capable of expressing the anti-IL-8 monoclonal antibody so as to prepare the anti-IL-8 monoclonal antibody; according to the invention, a variable region amino acid sequence of the anti-IL-8 monoclonal antibody is cloned at the same time; the anti-IL-8 monoclonal antibody disclosed by the invention can be specifically combined with IL-8, so that the anti-IL-8 monoclonal antibody can be used for treating diseases related to abnormal or excessive or out-of-control expression and secretion of the IL-8.

Methods, compositions and uses for inhibiting the growth in blood cancer cells with one or more of caffeic acid (3,4-dihydroxycinnamic acid) phenethyl ester (CAPE), CAPE analogue MT30, and CAPE analogue GL8. The blood cancer cells can be myeloma, lymphoma and leukemia cells. The methods, compositions and uses can be in conjunction with the use of an IMiD to treat a patient. The compositions can include a pharmaceutically acceptable carrier, adjuvant or vehicle, a pharmaceutically acceptable salt or dietary supplement.

The invention relates to the technical field of nano antibodies, in particular to an anti-FcRH5 nano antibody and application thereof. The invention provides an anti-FcRH5 nano antibody with high affinity and specificity, and the anti-FcRH5 nano antibody is based on a single-domain heavy chain variable region structure from camelidae and has the advantages of small molecular weight, high stability, strong tissue penetrability, easiness in engineering modification and the like. The nano antibody specifically recognizes and is combined with a high-expression and stable-expression target spot on the surface of a multiple myeloma cell through a complementary determining region of the nano antibody. The nano antibody disclosed by the invention can be used as a core recognition element for constructing various treatment or diagnosis tools such as chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates or immunodetection probes and the like. According to the technical scheme, the technical problem that an anti-FcRH5 antibody with high quality and definite functionality is lacked in the prior art can be solved. The nano antibody provided by the invention has remarkable clinical transformation and industrialization advantages, and promotes multiple myeloma treatment to multi-target collaborative iteration.

The invention discloses an anti-phenacetin monoclonal antibody hybridoma cell strain AD, a preparation method and application thereof, and relates to the technical field of food safety immunodetection. The monoclonal antibody hybridoma cell strain is named monoclonal cell strain AD and the number CGMCC19681. The Phe-BA obtained by the hydrolysis of the reaction product of the phenacetin metabolite acetaminophen and ethyl 4-bromobutyrate is used as the hapten, and the hapten is coupled with the carrier protein to prepare the immunogen Phe-BA-BSA. After the mice were immunized with the immunogen Phe-BA-BSA, they were fused with myeloma cells by PEG method, screened by indirect competitive enzyme-linked immunosorbent assay and subcloned five times to obtain hybridoma cell lines. The monoclonal antibody secreted by the cell line can be made into a phenacetin detection kit, which has good affinity and detection sensitivity for phenacetin, and can be used for immunodetection of phenacetin residues in food.

The invention belongs to the technical field of biological medicine, and particularly relates to multiple myeloma targeting nano microspheres and application thereof. The invention provides a delivery system for targeting multiple myeloma, the delivery system has different targeting molecules for bone targeting and cancer cell targeting, and multiple myeloma cells in a bone marrow microenvironment can be targeted. Furthermore, the delivery system is carried on the Selinexor, so that the selective delivery of the Selinexor on myeloma cells and affected bone tissues can be enhanced. In-vivo studies show that the delivery system significantly improves the treatment effect of MM. Malignant proliferation of myeloma cells is effectively inhibited, the bone density is increased, the bone microstructure is improved, and bone deterioration in an MM mouse model is relieved. The method for delivering the anti-MM drug through the dual-targeting nanoparticles represents an innovative strategy, MM cancer cell targeting and cancer microenvironment bone targeting are combined, and the method is never applied to MM treatment before.

The present application relates to the field of biotechnology and in vitro diagnosis, and relates to a monoclonal antibody of eosinophil peroxidase and application thereof. The antibody of the present application is mainly used for detecting the content of eosinophil peroxidase by western blot. The monoclonal antibody of eosinophil peroxidase of the present application is prepared by immunizing Balb / c mice with recombinant eosinophil peroxidase as an immunogen, then fusing the spleen with myeloma cells NS1, and screening and purifying. The prepared monoclonal antibody of eosinophil peroxidase specifically recognizes the linear epitope of eosinophil peroxidase.

The present invention provides a monoclonal antibody that recognizes a recombinant EGF-CRM197 vaccine and a preparation method thereof. Based on the research and development and preparation of a recombinant EGF-CRM197 vaccine, the present invention further immunizes mice with the recombinant EGF-CRM197 vaccine, fuses the mouse spleen cells with mouse myeloma cells, screens and produces a hybridoma cell line of specific monoclonal antibodies that recognize the recombinant EGF-CRM197 vaccine, and obtains the antibody sequence after sequencing. After the hybridoma cells are cultured in mice, monoclonal antibodies that recognize the recombinant EGF-CRM197 vaccine can be prepared in vitro by methods such as chromatography purification. The present invention can be used for the release potency detection of the recombinant EGF-CRM197 vaccine and for evaluating the immune efficacy after immunization with the recombinant EGF-CRM197 vaccine.

The invention discloses a series of colchicine deuterated derivatives for resisting multiple myeloma, which can effectively inhibit proliferation of multiple myeloma cells by improving the metabolic effect of colchicine in the multiple myeloma cells and overcome the defect of large toxic and side effects of metabolism of original drugs. According to the series of colchicine deuterated derivatives capable of resisting multiple myeloma, colchicine is used as a raw material, two reactions of demethylation and deuterated methyl are sequentially performed to obtain a target compound, the reaction steps are few, the reaction conditions are mild, the operability is high, and the efficiency is high.

The invention relates to the field of biotechnology and in vitro diagnosis, in particular to an anti-eosinophilic granulocyte peroxidase monoclonal antibody and application thereof. The antibody provided by the invention can directly and specifically capture eosinophilic granulocyte peroxidase with enzyme activity, and is used for biological research and clinical diagnosis of eosinophilic granulocytes. The monoclonal antibody for resisting eosinophilic granulocyte peroxidase is prepared by the following steps: taking recombinant eosinophilic granulocyte peroxidase as an immunogen to immunize a Balb / c mouse, then fusing the spleen with a myeloma cell NS1, and screening and purifying to obtain the monoclonal antibody for resisting eosinophilic granulocyte peroxidase. The prepared monoclonal antibody for resisting the eosinophilic granulocyte peroxidase specifically recognizes the epitope of the eosinophilic granulocyte peroxidase.

The invention discloses a method for inducing cell copper death based on GK921 and application of the GK921, and relates to the technical field of biological medicine. The invention discloses a brand new function of inducing copper death by a known compound GK921 for the first time, and provides a brand new strategy for solving the problems of drug resistance and relapse of multiple myeloma. According to the method, target cells are treated with an effective amount of GK921, expression of copper ion transporter ATP7A in the cells is specifically reduced, copper ions are accumulated, and then typical copper death events such as iron-sulfur cluster protein reduction and DLAT protein oligomerization are caused. Experiments show that the GK921 can efficiently inhibit the activity of multiple myeloma cell lines and primary cells, and the IC50 value and the low toxicity to normal cells show excellent selectivity. On the basis, GK921 can be used for preparing a pharmaceutical composition for inducing copper death, and particularly has an important application prospect in treatment of multiple myeloma.

The application relates to the technical field of bioengineering, in particular to a screening method of high-specificity monoclonal antibodies, which comprises the following steps: step S1: immunizing a mouse and separating and obtaining immune spleen cells, fusing the immune spleen cells with SP2 / 0 myeloma cells to obtain a hybridoma cell suspension; step S2: adopting a microfluidic single-cell sorting technology to wrap single hybridoma cells in the hybridoma cell suspension in microdroplets containing culture medium and capture antibodies, carrying out single-cell culture, and obtaining single-cell clones secreting monoclonal antibodies; the application has the advantages that the rare clone has a high acquisition rate: the application carries out detection at a single-cell level, can detect trace antibodies secreted by single cells, and avoids signal interference in multi-cell mixed culture. Meanwhile, through bright-field image assisted screening, microdroplets containing multiple cells can be effectively excluded, and it is ensured that each positive clone is from a single cell.

Provided are human therapeutic compositions including a compound comprising a plurality of fused polycyclic moieties and a linker moiety. In certain embodiments, the compound is a reaction product of an aldehyde and a harmine component. The compositions exhibit anti-cancer properties, particularly against lymphoma, leukemia, pancreatic, endometrial, ovarian, gastric, breast, renal, cervical, head and neck, and myeloma cell lines.

The application relates to the technical field of monoclonal antibodies, and specifically discloses an anti-p-Tau181 antibody and a preparation method and application thereof. The preparation method of the anti-p-Tau181 antibody comprises the following steps: taking a p-Tau181 polypeptide IPAKTPPAPK(pT)PPSSGEPPK as an immunogen, injecting the immunogen into experimental animals to perform an immune response, and obtaining spleen lymphocytes of the experimental animals; taking myeloma cells and the spleen lymphocytes to perform mixed culture to obtain fusion cells; culturing the fusion cells, obtaining supernatant, and performing ELISA detection; the polypeptide used for detection is the p-Tau181 polypeptide; taking the hybridoma cell strain with a positive detection result to perform counter screening with a p-Tau217 polypeptide, a p-Tau231 polypeptide and t-tau protein; screening a positive clone which has a reaction to the p-Tau181 polypeptide and has no reaction to the p-Tau217 polypeptide, the p-Tau231 polypeptide and the t-tau protein; performing multiple cloning screening; obtaining a hybridoma cell strain which can secrete antibodies every time; and taking the antibodies secreted by the hybridoma cell strain as the anti-p-Tau181 antibody. The anti-p-Tau181 antibody can be specifically combined with the p-Tau181, and thus can be used for detecting Alzheimer's disease.

The application provides an abnormal prothrombin detection kit and application thereof, and relates to the technical field of in-vitro detection.The application provides a kit for abnormal prothrombin detection, which comprises an abnormal prothrombin antibody, wherein the abnormal prothrombin antibody is derived from a hybridoma cell strain 7E8-4-4-1 of fusion of myeloma cells and mouse B cells, and the hybridoma cell strain 7E8-4-4-1 is preserved in the China General Microbiological Culture Collection Center on October 28, 2025, with a preservation number of CGMCC No.46709.The kit has a large detection range, a small lower limit of detection and high accuracy, and has great application potential in the detection of abnormal prothrombin.

The invention discloses a method for purifying a toxoplasma gondii recombinant antigen, which comprises the following steps: selecting a full-length sequence of a toxoplasma gondii surface antigen SRS3, connecting the full-length sequence with a carrier through enzyme digestion to form plasmids, performing mass expression in escherichia coli, sequentially performing ultrasonication and centrifugation to collect cell supernatant, and performing deep filtration; the specific affinity chromatography column is coupled with an IgG subtype antibody obtained by hybridizing splenocytes and myeloma cells of a BALB / c mouse infected with toxoplasma gondii through a hybridoma technology. And through affinity chromatography purification, the toxoplasma gondii antigen protein with relatively high purity is finally obtained. According to the method, the toxoplasma gondii recombinant antigen can be stably and effectively purified from the cell supernatant. The method provided by the invention has the advantages of high extraction purity, simple process, capability of realizing one-step purification, stable antibody and the like, and has important significance for realizing purification of the toxoplasma gondii recombinant antigen.

The invention provides an application of an ANXA1 protein or an antagonist thereof in preparation of a medicine for treating multiple myeloma. After the multiple myeloma BCMA immunotherapy, when BCMA negative recurrence occurs, in multiple myeloma cells, a BCMA receptor signal channel is reduced, ANXA1 protein expression quantity is increased, proliferation of the multiple myeloma cells is promoted, and CAR-T cell immunocompetence and immune persistence are inhibited at the same time. The antagonist of the ANXA1 protein reduces the expression quantity of the ANXA1 protein, inhibits the proliferation of multiple myeloma cells, and recovers the immunocompetence and immune persistence of CAR-T cells at the same time. According to the application, the biological function of the ANXA1 in the MM cells is defined, the action mechanism of the ANXA1 antagonist for treating the BCMA negative MM cells and improving the activity of the CAR-T cells is proved, a valuable theoretical basis is provided for improvement of clinical myeloma CAR-T cell treatment, and finally the disease-free lifetime of a patient after BCMA-targeted immunotherapy is prolonged.

The invention relates to a preparation method and application of hybridoma cells based on an electrofusion technology, the preparation method of the hybridoma cells based on the electrofusion technology comprises the following steps: taking splenocytes and myeloma cells of an antigen-immunized mouse for electrofusion, screening to obtain the hybridoma cells, and the antigen is serum amyloid protein A. The invention also relates to a preparation method of the hybridoma cells based on the electrofusion technology. The hybridoma cell capable of generating the serum amyloid protein A antibody is obtained in an electrofusion mode, the fusion efficiency of the hybridoma cell is improved, and the problem that the yield of the antibody is reduced due to the fact that the fusion efficiency of the hybridoma cell is low is solved.

The invention discloses an application of a CaMKII-gamma inhibitor serving as a bortezomib-resistant multiple myeloma treatment medicine. On the basis of si-RNA, cell proliferation activity can be inhibited by down-regulating expression of CaMKII-gamma in bortezomib-resistant multiple myeloma U266.BR cells and KMS11. BR cells, a small molecule compound rucotinib capable of effectively inhibiting activity of CaMKII-gamma kinase is obtained through high-throughput screening, growth of multiple myeloma U266 cells and KMS11 cells can be obviously inhibited, and the activity of the rucotinib can be effectively inhibited. The compound has an obvious inhibition effect on the growth of bortezomib-resistant multiple myeloma U266.BR cells and KMS11. BR cells, also has an obvious inhibition effect on the growth of U266.BR transplantation tumors, and shows a good tumor inhibition effect as a potential medicine for treating multiple myeloma and bortezomib-resistant multiple myeloma.

The invention provides an anti-medetomidine monoclonal antibody as well as application and a product thereof, and relates to the technical field of biology. Medetomidine is used for immunizing a Balb / c mouse, splenocytes of the mouse are fused with myeloma cells, hybridoma cells with high specificity are obtained through specific high-throughput screening, a large amount of mouse ascites is obtained through culture and re-immunization, and the mouse ascites with high specificity is obtained. And the medetomidine monoclonal antibody with high purity, high sensitivity and high specificity is obtained through multi-step separation and purification, so that a required raw material is provided for developing an immune test strip for detecting medetomidine. The anti-medetomidine monoclonal antibody disclosed by the invention can be used for immunological detection such as immunoblotting and immunofluorescence, and the obtained antibody is proved to have good specific binding capacity.

The invention belongs to the field of biology, and discloses a preparation method of hybridoma cells, which comprises the following steps: immunizing a mouse with eukaryotic expression IFN-gamma-His protein for multiple times, carrying out cell fusion and culture on spleen cells of the mouse and myeloma SP2 / 0 cells to obtain monoclonal cells, and screening the monoclonal cells to obtain the hybridoma cells; the IFN-gamma-His protein is obtained by expressing a duck IFN-gamma gene with a His tag in a eukaryotic cell. The hybridoma cell line can stably secrete the mouse anti-duck IFN-gamma monoclonal antibody 24H4, and can be used for detecting the expression change of duck immune cells IFN-gamma by flow cytometry. Meanwhile, the invention also discloses a monoclonal antibody as well as application and a detection method thereof.

The invention relates to the technical field of nano antibodies, in particular to an anti-FcRH5 nano antibody and application thereof. The invention provides an anti-FcRH5 nano antibody with high affinity and specificity, and the anti-FcRH5 nano antibody is based on a single-domain heavy chain variable region structure from camelidae and has the advantages of small molecular weight, high stability, strong tissue penetrability, easiness in engineering modification and the like. The nano antibody specifically recognizes and is combined with a high-expression and stable-expression target spot on the surface of a multiple myeloma cell through a complementary determining region of the nano antibody. The nano antibody disclosed by the invention can be used as a core recognition element for constructing various treatment or diagnosis tools such as chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates or immunodetection probes and the like. According to the technical scheme, the technical problem that an anti-FcRH5 antibody with high quality and definite functionality is lacked in the prior art can be solved. The nano antibody provided by the invention has remarkable clinical transformation and industrialization advantages, and promotes multiple myeloma treatment to multi-target collaborative iteration.

The invention provides an anti-trihexylol monoclonal antibody as well as application and a product thereof, and relates to the technical field of biology. The method comprises the following steps: immunizing a Balb / c mouse by using trihexylamine, fusing splenocytes of the mouse with myeloma cells, carrying out specific high-throughput screening to obtain hybridoma cells with high specificity, and carrying out culture and re-immunization to obtain a large amount of mouse ascites. And the monoclonal antibody resisting the trihexylamine with high purity, high sensitivity and high specificity is obtained through multi-step separation and purification, so that a required raw material is provided for developing an immune test strip for detecting the trihexylamine. Through verification, the monoclonal antibody for resisting the trihexylamine disclosed by the invention has good specific binding capacity.

The invention provides application of a c-Myc G4 targeting small molecule drug in preparation of a drug for treating multiple myeloma, and belongs to the technical field of multiple myeloma. The pharmaceutical composition for treating multiple myeloma provided by the invention takes a compound shown as a formula Y502-2304 or a pharmaceutically acceptable salt thereof as an active ingredient or a main active ingredient, and is supplemented with a pharmaceutically acceptable carrier. In multiple myeloma, the compound Y502-2304 regulates apoptosis and cycle progress of cells by stabilizing the c-Myc G4 structure, promotes death of myeloma cells, can be used as a drug for treating multiple myeloma, and provides a new thought for research and development of drugs for resisting multiple myeloma. # imgabs0 #

The invention relates to the field of biotechnology and in vitro diagnosis, in particular to a monoclonal antibody of eosinophilic granulocyte peroxidase and application of the monoclonal antibody. The antibody disclosed by the invention is mainly used for detecting the content of peroxidase in eosinophilic granulocytes by using western blot. The monoclonal antibody for resisting eosinophilic granulocyte peroxidase is prepared by the following steps: taking recombinant eosinophilic granulocyte peroxidase as an immunogen to immunize a Balb / c mouse, then fusing the spleen with a myeloma cell NS1, and screening and purifying to obtain the monoclonal antibody for resisting eosinophilic granulocyte peroxidase. The prepared monoclonal antibody for resisting the eosinophilic granulocyte peroxidase specifically recognizes the linear epitope of the eosinophilic granulocyte peroxidase.

This invention provides a monoclonal antibody against the VP2 protein of a mandarin fish two-segmented RNA virus, its preparation method, and its application. The VP2 protein was obtained by expression and purification using recombinant plasmids. Mice were immunized three times, and mice with the highest serum titer were selected for intraperitoneal booster immunization against VP2 protein. Mouse spleen cells and SP2 / 0 myeloma cells were fused, and hybridoma cell lines secreting VP2 protein antibodies were screened. These cells were then subcloned to obtain four stable hybridoma cell lines secreting anti-VP2 protein antibodies, and their heavy and light chain variable region sequences were determined. Mice were injected intraperitoneally with Freund's incomplete adjuvant, followed by the injection of the hybridoma cell lines. Ascites fluid was collected from the mice, extracted, purified, and used to obtain the monoclonal antibody against the VP2 protein. Using these four monoclonal antibodies, three highly conserved and specific antigenic epitopes of the VP2 protein of the mandarin fish two-segmented RNA virus were screened and identified. This invention provides support for establishing specific serological methods for mandarin fish two-segmented RNA viruses and for further research on the biological function and clinical diagnosis of VP2.

A blocking monoclonal antibody screening method based on a porcine PD-1 / PD-L1 monoclonal antibody and a heterologous Fc fusion protein comprises the following steps: (a) preparing a porcine PD-1 or PD-L1 extracellular region recombinant protein; (b) immunizing mice by using the recombinant protein to obtain immune spleen cells; (c) fusing the immune spleen cells with myeloma cells to obtain hybridoma cells; (d) screening and subcloning a hybridoma cell strain capable of secreting an anti-porcine PD-1 or PD-L1 antibody; (e) preparing a porcine PD-L1-rabbit Fc fusion protein; and (f) evaluating the blocking effect of the monoclonal antibody on PD-1 / PD-L1 binding by using the PD-L1-rabbit Fc fusion protein through flow cytometry.